🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "major milestone" in the battle against drug-resistant strains of the infection, according to health experts.

A Global Challenge

Cases of gonorrhoea are escalating worldwide, with figures suggesting more than 82 million infections annually. Particularly high rates are reported in Africa and countries within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely step in the reality of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce available drugs presently on offer.”

Medical experts are particularly alarmed about the increase in treatment-resistant strains. The WHO has classified it as a "priority pathogen". Ongoing monitoring showed that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Receive Clearance

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in mid-December for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers hope that focused deployment of this new drug will help delay the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This drug, which is additionally indicated for UTIs, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This approval signifies a significant shift in the management of superbug gonorrhoea, which until now has been outpacing our drug pipeline.”

Testing Results and Worldwide Availability

According to findings released by a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This puts it on an similar efficacy with the current standard treatment, which involves two antibiotics. The research enrolled hundreds of participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the rights to license and sell the drug in numerous regions with limited resources.

Doctors treating patients have shared optimism. The availability of a one-pill regimen of this kind is seen as a "game-changer" for gonorrhoea control. This is considered crucial to lessen the impact of the infection for people and to halt the transmission of extremely resistant gonorrhoea worldwide.